Clinical Trials

12 results for Prostate Cancer


A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer

  • Condition: Prostate Cancer, Prostate Adenocarcinoma
  • Intervention: Drug: ADT+Docetaxel+Enzalutamide
  • Study ID: NCT03246347
View Trial

Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)

  • Condition: Prostate Cancer
  • Intervention: Other: Standard of Care
  • Study ID: NCT03151629
View Trial

Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer

  • Condition: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
  • Intervention: Biological: GnRH agonist/antagonist, Drug: Prednisone, Drug: Abiraterone Acetate, Drug: Enzalutamide
  • Study ID: NCT03016741
View Trial

Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)

  • Condition: Prostate Cancer Metastatic
  • Intervention: Drug: Rucaparib
  • Study ID: NCT03413995
View Trial

A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR)

  • Condition: Prostate Cancer
  • Intervention: Drug: Rucaparib
  • Study ID: NCT03533946
View Trial

Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

  • Condition: Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Can
  • Intervention: Drug: Abiraterone Acetate, Drug: Antiandrogen Therapy, Drug: Cabazitaxel, Other: Laboratory Biomarker Analysis, Procedure: Orchiectomy, Other: Pharmacological Study, Drug: Prednisone
  • Study ID: NCT03419234
View Trial

Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study

  • Condition: Prostate Cancer, Bone Metastases
  • Intervention: Drug: Zoledronic Acid, Drug: Enzalutamide
  • Study ID: NCT03336983
View Trial

A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer

  • Condition: Prostate Adenocarcinoma
  • Intervention: Drug: Leuprolide Acetate, Drug: Goserelin Acetate, Radiation: Stereotactic Body Radiation Therapy, Radiation: Radium Ra 223 Dichloride, Other: Laboratory Biomarker Analysis
  • Study ID: NCT03361735
View Trial

Randomized Phase 1b/2 Study of Nivolumab or Nivolumab Plus BMS-986253 in Combination With Intermittent Androgen Deprivation Therapy in Men With Hormone-Sensitive Prostate Cancer

  • Condition: Prostate Cancer, Adenocarcinoma of the Prostate
  • Intervention: Drug: Nivolumab, Drug: Degarelix, Drug: BMS-986253
  • Study ID: NCT03689699
View Trial

A Phase II Study of Olaparib and Durvalumab in Men With Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer Harboring Mutations in DNA Damage Repair

  • Condition: Prostate Cancer
  • Intervention: Drug: Olaparib, Drug: Durvalumab
  • Study ID: NCT03810105
View Trial

SAABR: Single-Arm Phase II Study of Abiraterone Acetate + Atezolizumab + Lupron and Stereotactic Body Radiotherapy (SBRT) to the Prostate in Men With Newly Diagnosed Hormone-sensitive Metastatic Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Intervention: Drug: Atezolizumab, Drug: Abiraterone, Drug: Prednisone, Drug: Lupron, Radiation: Stereotactic Body Radiotherapy (SBRT)
  • Study ID: NCT04262154
View Trial

A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate Cancer

  • Condition: Metastatic Prostate Cancer
  • Study ID: NCT04332744
View Trial